BioMarin Pharmaceutical, Inc. (BMRN)
57.18
-1.26
(-2.16%)
USD |
NASDAQ |
Oct 02, 16:00
57.30
+0.12
(+0.21%)
After-Hours: 20:00
BioMarin Pharmaceutical Profit Margin (Quarterly) : 4.49% for June 30, 2026
Profit Margin (Quarterly) Chart
Historical Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 4.49% |
| March 31, 2026 | 13.55% |
| December 31, 2025 | -5.20% |
| September 30, 2025 | -3.91% |
| June 30, 2025 | 29.07% |
| March 31, 2025 | 25.35% |
| December 31, 2024 | 16.92% |
| September 30, 2024 | 14.29% |
| June 30, 2024 | 15.12% |
| March 31, 2024 | 13.64% |
| December 31, 2023 | 3.15% |
| September 30, 2023 | 6.89% |
| June 30, 2023 | 9.42% |
| March 31, 2023 | 8.58% |
| December 31, 2022 | -0.05% |
| September 30, 2022 | -1.36% |
| June 30, 2022 | 5.24% |
| March 31, 2022 | 23.51% |
| December 31, 2021 | -13.02% |
| September 30, 2021 | -8.94% |
| June 30, 2021 | 2.57% |
| March 31, 2021 | 3.55% |
| December 31, 2020 | 4.90% |
| September 30, 2020 | |
| June 30, 2020 | -6.93% |
| Date | Value |
|---|---|
| March 31, 2020 | 16.42% |
| December 31, 2019 | 3.35% |
| September 30, 2019 | 12.10% |
| June 30, 2019 | -9.76% |
| March 31, 2019 | -14.12% |
| December 31, 2018 | -1.04% |
| September 30, 2018 | -3.26% |
| June 30, 2018 | -4.46% |
| March 31, 2018 | -11.58% |
| December 31, 2017 | -14.13% |
| September 30, 2017 | -3.70% |
| June 30, 2017 | -11.64% |
| March 31, 2017 | -5.43% |
| December 31, 2016 | -30.23% |
| September 30, 2016 | -13.44% |
| June 30, 2016 | -139.3% |
| March 31, 2016 | -35.56% |
| December 31, 2015 | 30.10% |
| September 30, 2015 | -44.46% |
| June 30, 2015 | -33.33% |
| March 31, 2015 | -34.00% |
| December 31, 2014 | -30.23% |
| September 30, 2014 | 4.22% |
| June 30, 2014 | -17.40% |
| March 31, 2014 | -25.20% |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Profit Margin (Quarterly) Benchmarks
| Alnylam Pharmaceuticals, Inc. | 12.74% |
| Vertex Pharmaceuticals, Inc. | 32.89% |
| Ascendis Pharma A/S | 61.00% |
| BridgeBio Pharma, Inc. | -63.97% |
| Incyte Corp. | 34.98% |
Profit Margin (Quarterly) Related Metrics
| Return on Equity | 1.19% |
| Return on Assets | 0.85% |
| Return on Invested Capital | 0.95% |
| Gross Profit Margin (Quarterly) | 72.27% |
| Operating Margin (Quarterly) | 20.52% |
| Return on Net Operating Assets | 1.53% |